Cytokinetics (CYTK) Tops Q4 EPS by 17c, Comments on Outlook for 2009
Tweet Send to a Friend
Cytokinetics, Inc. (Nasdaq: CYTK) reports a Q4 loss of $0.22, 17 cents better than the analyst estimate of ($0.39). Revenue ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
